Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23234642 | 0.84 | KDM4E (0.34) | KDM4EKMT2AP2RX3P2RX2SMN1; SMN2 | |
| SCHEMBL8986715 | 0.78 | — | — | |
| SCHEMBL20681196 | 0.76 | KDM4E (0.32) | KDM4EKMT2AP2RX3P2RX2 | |
| SCHEMBL3169248 | 0.73 | UHRF1 (0.41) | KDM4EKMT2A | |
| SCHEMBL3840770 | 0.73 | NOS3 (0.42) | KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL20285958 | 0.73 | LMNA (0.32) | — | |
| SCHEMBL20242364 | 0.71 | KDM4E (0.36) | KDM4EKMT2A | |
| SCHEMBL21542734 | 0.71 | NOS3 (0.40) | KDM4EKMT2AP2RX3P2RX2 | |
| SCHEMBL30154660 | 0.71 | NOS3 (0.40) | KDM4EKMT2AP2RX3P2RX2 | |
| SCHEMBL20673581 | 0.70 | KDM5B (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3826721-B1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20210253580-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2020023551-A1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253580-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HIPK1, HPGDS, IP6K1 | KDM4E 1953/4885KMT2A 1032/4885P2RX3 3833/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | KDM4E 2318/4885KMT2A 4093/4885P2RX3 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.